A number of firms have modified their ratings and price targets on shares of DBV Technologies (NASDAQ: DBVT) recently:

  • 9/12/2017 – DBV Technologies had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $51.00 price target on the stock.
  • 9/12/2017 – DBV Technologies was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $49.00 price target on the stock. According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “
  • 9/8/2017 – DBV Technologies was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “
  • 8/31/2017 – DBV Technologies had its “buy” rating reaffirmed by analysts at Jefferies Group LLC.
  • 8/31/2017 – DBV Technologies was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “
  • 8/29/2017 – DBV Technologies was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $50.00 price target on the stock. According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “
  • 8/25/2017 – DBV Technologies had its price target raised by analysts at Leerink Swann from $54.00 to $60.00. They now have an “outperform” rating on the stock.
  • 8/22/2017 – DBV Technologies was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 8/11/2017 – DBV Technologies was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 8/1/2017 – DBV Technologies was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. They now have a $49.00 price target on the stock. According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “
  • 7/25/2017 – DBV Technologies was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.

DBV Technologies S.A. (DBVT) traded down 0.34% during mid-day trading on Wednesday, hitting $43.82. 24,578 shares of the company traded hands. DBV Technologies S.A. has a one year low of $31.87 and a one year high of $46.33. The firm has a 50 day moving average of $44.12 and a 200 day moving average of $37.54. The firm’s market capitalization is $2.02 billion.

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Receive News & Stock Ratings for DBV Technologies SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies SA and related stocks with our FREE daily email newsletter.